Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
MedStar Washington Hospital Center · University of Ulsan · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
998
total citations
- FWCI
- 55.09
- Percentile
- 100%
- References
- 36
Citations per year
Authors
14- SMSandra M. SwainCorresponding
MedStar Washington Hospital Center
- SKSung‐Bae Kim
University of Ulsan, Asan Medical Center, Ulsan College
- JCJavier Cortés
Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Universitari
- JRJungsil Ro
National Cancer Center
- SVSemiglazov Vf
Institute of Oncology NN Petrov
Topics & keywords
Topics
Keywords
- Pertuzumab
- Medicine
- Docetaxel
- Clinical endpoint
- Internal medicine
- Trastuzumab
- Oncology
- Metastatic breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.